Form 4: United Therapeutics COO Executes Pre-Planned Stock Sale

United Therapeutics' President and COO, Michael Benkowitz, completed a pre-scheduled exercise of stock options and subsequent sale of common stock.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), executed transactions on January 12, 2026, involving the exercise of stock options and the sale of common stock.
• A total of 14,625 shares were acquired through option exercise at a price of $117.76 per share and subsequently sold at $479.5056 per share. These shares were held in a trust where Mr. Benkowitz is a beneficiary and co-trustee with his spouse.
• An additional 7,875 shares were acquired through option exercise at a price of $146.03 per share and subsequently sold at $479.5056 per share. These shares were held in a trust where Mr. Benkowitz's family members are beneficiaries, and he has sole investment and voting power.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• Following these transactions, Mr. Benkowitz directly owns 2,648 shares of common stock.
• He also beneficially owns 82,500 stock options related to the first trust and 44,440 stock options related to the second trust, with expiration dates of March 15, 2027.

Sentiment

Score: 7

Explanation: The transaction represents a pre-planned, profitable exercise of options and sale of shares by a key executive, which is a routine event under a 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-arranged nature and retained holdings mitigate concerns, suggesting a neutral to slightly positive sentiment.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information, which often mitigates negative market perception of insider selling.
• The sale price of $479.5056 per share is significantly higher than the exercise prices of $117.76 and $146.03, indicating a substantial profit for the executive on these transactions.
• The executive retains a significant number of unexercised stock options (126,940 total) and direct share ownership (2,648 shares), maintaining alignment with shareholder interests.

Negatives

• Insider selling, even when pre-planned, can sometimes be interpreted by the market as a lack of confidence, although the 10b5-1 plan typically lessens this concern.

Future Outlook

This Form 4 filing is purely transactional and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction reflects an executive's personal financial planning and monetization of equity compensation, rather than a direct indicator of broader industry trends or competitive positioning. The profitability of the option exercise and sale suggests a favorable stock performance for United Therapeutics leading up to the transaction date.

Related Party Transactions

• The transactions involved shares held in trusts where the reporting person is a beneficiary, and in one case, a co-trustee with his spouse, and in another, where his family members are beneficiaries and he has sole investment and voting power. These are considered related party dealings in the context of beneficial ownership reporting.

Stakeholder Impact

• Shareholders may note the insider sale, but the pre-arranged nature under a Rule 10b5-1 plan typically reduces any negative interpretation regarding management's confidence in the company's future.
• The executive's continued significant holdings of stock options align his interests with long-term shareholder value.

Key Dates

Recommendation

The filing details a pre-scheduled insider sale of shares following option exercise, which is a routine event and does not typically signal a change in the company's fundamental outlook. The executive retains significant option holdings. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's performance and strategic direction.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Michael Benkowitz, Share Sale, Beneficial Ownership, Executive Compensation